stockrowGlaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +112.2%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
Follow GKOS
Alert me
Glaukos Corporation (GKOS) Shares outstanding
Glaukos Corporation's shares outstanding at the end of fiscal 2025 was $57.2M, up 8.41% from $52.8M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $61.2M. Over the past ten years it has ranged from $17.5M (fiscal 2015) to $57.2M (fiscal 2025) — the current reading is the highest in ten years. Glaukos Corporation ranks 47th of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $57.2M | 8.41% |
| FY2024 | $52.8M | 8.92% |
| FY2023 | $48.4M | 2.08% |
| FY2022 | $47.4M | 2.20% |
| FY2021 | $46.4M | 4.33% |
| FY2020 | $44.5M | 8.15% |
| FY2019 | $41.1M | 16.50% |
| FY2018 | $35.3M | 2.72% |
| FY2017 | $34.4M | (5.70%) |
| FY2016 | $36.5M | 108.65% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $61.2M | 4.04% |
| Jun 2026 | $58.8M | 1.37% |
| Mar 2026 | $58.0M | 1.45% |
| Dec 2025 | $57.2M | (0.36%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| ZBH Zimmer Biomet Holdings, Inc. compare | $191.4M |
| BRKR Bruker Corporation compare | $152.5M |
| GMED Globus Medical, Inc. compare | $136.0M |
| PODD Insulet Corporation compare | $69.5M |
| GKOS Glaukos Corporation | $61.2M |
| PEN Penumbra, Inc. compare | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on GKOS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement